Intensity Therapeutics Inc. Common stock (INTS)

About INTS

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

5

Website

www.intensitytherapeutics.com

Fundamentals

1-day range

$4.24$4.58

Market cap

$11.51M

P/E (trailing)

—

P/E (forward)

-2.13

EPS (trailing)

$-7.18

Dividend yield

—

Beta

2.97

Avg. volume

45.2K

Forecasts

6 analyst ratings

Intensity Therapeutics Inc. Common stock Competitors

Chosen by industry and closest market cap.

• INTS

  Intensity Therapeutics Inc. Common stock

  $4.25

  ▲ 0.95%
  Market cap $11.51MP/E —
  $3.51$43.5
• SNTI

  Senti Biosciences Holdings Inc. Common Stock

  $0.377

  ▼ 0.26%
  Market cap $11.53MP/E —
  $0.3305$2.88
• CRIS

  Curis Inc. Common Stock

  $1.49

  ▲ 2.76%
  Market cap $10.04MP/E —
  $1.4$39
• BCDA

  BioCardia Inc. Common Stock

  $1.16

  ▼ 0.85%
  Market cap $9.45MP/E —
  $0.75$2.29
• PASG

  Passage Bio Inc. Common Stock

  $4.52

  ▲ 4.39%
  Market cap $14.40MP/E —
  $3.29$20
• AIM

  AIM ImmunoTech Inc. Common Stock

  $0.2558

  ▲ 2.32%
  Market cap $7.32MP/E —
  $0.1901$2.89
• JSPR

  Jasper Therapeutics Inc. Common Stock

  $0.6782

  ▼ 2.98%
  Market cap $16.98MP/E —
  $0.3151$2.96

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Maintains Buy on Intensity Therapeutics, Raises Price Target to $7
  Benzinga · 8/18/2026
• Intensity Therapeutics, Inc. Q2 2026 Earnings Call Summary
  Yahoo · 8/12/2026
• Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript
  Yahoo · 8/12/2026
• Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/11/2026
• Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
  Yahoo · 8/11/2026
• Intensity Therapeutics Q2 EPS $(1.11), Inline
  Benzinga · 8/11/2026
• Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
  Yahoo · 8/4/2026

• Donovan Daniel · July 16, 2026 · Grant

  5.5K
• John M. Wesolowski · July 16, 2026 · Grant

  11.0K
• Leahy Emer · July 16, 2026 · Grant

  5.5K
• Joseph Talamo · July 16, 2026 · Grant

  34.0K
• GOLDBERG MARK A · July 16, 2026 · Grant

  5.5K
• Lewis H. Bender · July 16, 2026 · Grant

  78.0K
• DUBIN THOMAS I H · July 16, 2026 · Grant

  5.5K
• John M. Wesolowski · June 30, 2026 · Grant

  3.7K @ $3.49
• Joseph Talamo · June 30, 2026 · Grant

  1.1K @ $3.49
• Lewis H. Bender · March 26, 2026 · Grant

  37.7K @ $6.11

Institutional Ownership

March 31, 2026

Total shares held

132.0K

Total value held

$775.9K

Institutional holders

11